Malignant melanoma in the 21st century, part 2: Staging, prognosis, and treatment

Svetomir N. Markovic, Lori A. Erickson, Ravi D. Rao, Roger H. Weenig, Barbara A. Pockaj, Aditya Bardia, Celine M. Vachon, Steven E. Schild, Robert R. McWilliams, Jennifer L. Hand, Susan D. Laman, Lisa A. Kottschade, William J. Maples, Mark R. Pittelkow, Jose S. Pulido, J. Douglas Cameron, Edward T. Creagan

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Abstract

Critical to the clinical management of a patient with malignant melanoma is an understanding of its natural history. As with most malignant disorders, prognosis is highly dependent on the clinical stage (extent of tumor burden) at the time of diagnosis. The patient's clinical stage at diagnosis dictates selection of therapy. We review the state of the art in melanoma staging, prognosis, and therapy. Substantial progress has been made in this regard during the past 2 decades. This progress is primarily reflected in the development of sentinel lymph node biopsies as a means of reducing the morbidity associated with regional lymph node dissection, increased understanding of the role of neoangiogenesis in the natural history of melanoma and its potential as a treatment target, and emergence of innovative multimodal therapeutic strategies, resulting in significant objective response rates in a disease commonly believed to be drug resistant. Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach.

Original languageEnglish (US)
Pages (from-to)490-513
Number of pages24
JournalMayo Clinic Proceedings
Volume82
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint Dive into the research topics of 'Malignant melanoma in the 21st century, part 2: Staging, prognosis, and treatment'. Together they form a unique fingerprint.

Cite this